CA2207246A1 - Preparation de vaccin - Google Patents

Preparation de vaccin

Info

Publication number
CA2207246A1
CA2207246A1 CA 2207246 CA2207246A CA2207246A1 CA 2207246 A1 CA2207246 A1 CA 2207246A1 CA 2207246 CA2207246 CA 2207246 CA 2207246 A CA2207246 A CA 2207246A CA 2207246 A1 CA2207246 A1 CA 2207246A1
Authority
CA
Canada
Prior art keywords
cell
antigen
adjuvant
vaccine
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2207246
Other languages
English (en)
Inventor
Andrew William Heath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adjuvantix Ltd
Original Assignee
University of Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sheffield filed Critical University of Sheffield
Priority to CA 2207246 priority Critical patent/CA2207246A1/fr
Publication of CA2207246A1 publication Critical patent/CA2207246A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA 2207246 1997-06-06 1997-06-06 Preparation de vaccin Abandoned CA2207246A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2207246 CA2207246A1 (fr) 1997-06-06 1997-06-06 Preparation de vaccin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2207246 CA2207246A1 (fr) 1997-06-06 1997-06-06 Preparation de vaccin

Publications (1)

Publication Number Publication Date
CA2207246A1 true CA2207246A1 (fr) 1998-12-06

Family

ID=4160849

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2207246 Abandoned CA2207246A1 (fr) 1997-06-06 1997-06-06 Preparation de vaccin

Country Status (1)

Country Link
CA (1) CA2207246A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015728A1 (fr) * 1999-08-27 2001-03-08 University Health Network Procede d'activation de lymphocytes t cytotoxiques (ctls) in vivo: composition comprenant un anticorps anti cd40 (ou cd40l ou une proteine liant le cd40) et un antigene
EP1469881A2 (fr) * 2002-01-28 2004-10-27 Adjuvantix Limited Adjuvant de vaccin a base d'un ligand cd40

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015728A1 (fr) * 1999-08-27 2001-03-08 University Health Network Procede d'activation de lymphocytes t cytotoxiques (ctls) in vivo: composition comprenant un anticorps anti cd40 (ou cd40l ou une proteine liant le cd40) et un antigene
EP1469881A2 (fr) * 2002-01-28 2004-10-27 Adjuvantix Limited Adjuvant de vaccin a base d'un ligand cd40

Similar Documents

Publication Publication Date Title
US20020136722A1 (en) Vaccination method
Dullforce et al. Enhancement of T cell-independent immune responses in vivo by CD40 antibodies
Insel et al. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants.
Wheeler et al. A Th1-inducing adjuvant, MPL®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines
TWI227241B (en) IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
DE69636312T2 (de) Rezeptorspezifischer Transepithelealer Transport von Immunogenen
KR100290632B1 (ko) 면역성이약한항원공액체와이를포함하는합성펩티드담체와백신
US5194254A (en) Enhancement of antigen immunogenicity
US5955079A (en) Dual carrier immunogenic construct
US4950480A (en) Enhancement of antigen immunogenicity
Barr et al. A potent adjuvant effect of CD40 antibody attached to antigen
KR100263359B1 (ko) IgE 관련 알레르기 반응의 치료용 IgE의 입실론 사슬의 정상부로 구성된 백신
EP1569688B1 (fr) VACCIN CONTENANT UN ANTIGENE CONJUGUE A DES ANTICORPS ANTI-CD40& xA;. DE FAIBLE VALENCE
EP0542923B1 (fr) Liposomes fournissant une aide thymodependante a des antigenes de vaccin faibles
Vella et al. Immunogenicity of a new Haemophilus influenzae type b conjugate vaccine (Meningococcal protein conjugate)(PedvaxHIBTM)
Lees et al. Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules
Bjarnarson et al. The advantage of mucosal immunization for polysaccharide‐specific memory responses in early life
US20020086026A1 (en) Novel vaccine development
CA2207246A1 (fr) Preparation de vaccin
Lee et al. Suppression of Reaginic Antibody Formation: III. Relationship Between Immunogenicity and Tolerogenicity of Hapten-Carrier Conjugates
CA2082425A1 (fr) Composition pour vaccin
EP1155037A1 (fr) Epitopes ou mimotopes derives du domaine c-epsilon-2 de l'immoglobuline e, leurs antagonistes et leurs applications therapeutiques
Sverremark et al. Immunogenicity of bacterial carbohydrates: cholera toxin modulates the immune response against dextran B512.
Colino et al. Dynamics of the murine humoral immune response to Neisseria meningitidis group B capsular polysaccharide
AU703300B2 (en) Use of muteins of wild-type cytokines as immunogens

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead